February 7, 2025
Recombinant Adeno-Associated Virus (rAAV) Technology  Pioneered by AskBio’s Dr. Jude Samulski is Key Component  of All FDA Approved AAV Gene Therapeutics

Research Triangle Park, N.C. (December 20, 2022) – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated subsidiary of Bayer AG, today announced that the FDA’s approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder…
Read More

About The Author

Leave a Reply

Your email address will not be published. Required fields are marked *